ISU Abxis
Korea - SeongnamBiotechnology
Focus: ISU Abxis is a Korean biotech company focused on biologics development in rare diseases and oncology. The company operates as a mid-cap biotech with a diversified pipeline across multiple therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About ISU Abxis
AI assessmentNot HiringNo open roles listed right now. Follow ISU Abxis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
Gaucher DiseaseClinical Trials (1)
NCT02053896A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
N/AHelp build intelligence for ISU Abxis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.